Carter M. Suryadevara Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery Duke University Biography Publications Institution JoVE Articles Carter M. Suryadevara has not added a biography. If you are Carter M. Suryadevara and would like to personalize this page please email our Author Liaison for assistance. Publications Chimeric Antigen Receptor Engineered T Cells Can Eliminate Brain Tumors and Initiate Long-term Protection Against Recurrence Oncoimmunology. 2014 | Pubmed ID: 25610729 Leveraging Chemotherapy-induced Lymphopenia to Potentiate Cancer Immunotherapy Oncoimmunology. 2014 | Pubmed ID: 25610727 Epidermal Growth Factor Receptor and Variant III Targeted Immunotherapy Neuro-oncology. Oct, 2014 | Pubmed ID: 25342601 EGFRvIII-specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma PloS One. 2014 | Pubmed ID: 24722266 EGFRvIII MCAR-modified T-cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity Against Tumor-antigen Loss Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2014 | Pubmed ID: 24352643 Intracerebral Delivery of a Third Generation EGFRvIII-specific Chimeric Antigen Receptor is Efficacious Against Human Glioma Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. Jan, 2014 | Pubmed ID: 24054399 Генерация CAR Т-клеток в усыновители терапии в контексте глиобластомы стандарт медицинской помощи Katherine Riccione1,2, Carter M. Suryadevara1,3, David Snyder1, Xiuyu Cui1, John H. Sampson1,2,3, Luis Sanchez-Perez1 1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University, 2Department of Biomedical Engineering, Duke University, 3Department of Pathology, Duke University Immunology and Infection
Генерация CAR Т-клеток в усыновители терапии в контексте глиобластомы стандарт медицинской помощи Katherine Riccione1,2, Carter M. Suryadevara1,3, David Snyder1, Xiuyu Cui1, John H. Sampson1,2,3, Luis Sanchez-Perez1 1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University, 2Department of Biomedical Engineering, Duke University, 3Department of Pathology, Duke University Immunology and Infection
